Seattle Genetics drops under ASH cloud as PD-1s hog limelight
This article was originally published in Scrip
Seattle Genetics saw its share price drop 7% on 8 December despite positive data presentations at the American Society of Hematology (ASH) annual meeting. Investors are concerned that Adcetris (brentuximab vedotin), which it is developing in collaboration with Takeda, will not fare well against competing therapies in Hodgkin lymphoma, namely the PD-1 drugs Merck & Co's pembrolizumab and Bristol-Myers-Squibb's nivolumab.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.